International Immunology, Vol. 13, No. 4, 459-463,
April 2001
© 2001 Japanese Society for Immunology
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Cancer Immunology, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria 8006, Australia
1 Department of Pathology and Immunology, Monash University Medical School, Prahran, Victoria 3181, Australia
Correspondence to: M. Smyth, Cancer Immunology, Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, Victoria, Australia
NK1.1+ V
14J281+ (NKT) cells can be induced by IL-12 therapy to mediate tumor rejection; however, methylcholanthrene (MCA)-induced fibrosarcoma is the only tumor model described where NKT cells play a natural role in controlling tumor initiation. From our previous study in C57BL/6 mice it remained unclear whether NK cells were also involved in this natural response. Herein, to discriminate the function of NK and NKT cells, we have evaluated fibrosarcoma development in mice deficient in NKT cells, but not NK cells, and mice deficient in NK cells, but not NKT cells. The results indicate that both NK cells and NKT cells are essential and collaborate in natural host immunity against MCA-induced sarcoma. In contrast, sarcoma incidence and growth rate were reduced using IL-12 therapy, this effect was mediated in the absence of T cells (including NKT cells), but not NK cells.
Keywords: immunotherapy, in vivo animal model, NK cell, NKT cell, tumor immunity
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. J. Chan, D. M. Andrews, N. M. McLaughlin, H. Yagita, S. Gilfillan, M. Colonna, and M. J. Smyth DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases J. Immunol., January 15, 2010; 184(2): 902 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sondergaard, J. M. Coquet, A. P. Uldrich, N. McLaughlin, D. I. Godfrey, P. V. Sivakumar, K. Skak, and M. J. Smyth Endogenous IL-21 Restricts CD8+ T Cell Expansion and Is not Required for Tumor Immunity J. Immunol., December 1, 2009; 183(11): 7326 - 7336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Swann, A. P. Uldrich, S. van Dommelen, J. Sharkey, W. K. Murray, D. I. Godfrey, and M. J. Smyth Type I natural killer T cells suppress tumors caused by p53 loss in mice Blood, June 18, 2009; 113(25): 6382 - 6385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. L. Teng, S. Yue, J. Sharkey, M. A. Exley, and M. J. Smyth CD1d Activation and Blockade: A New Antitumor Strategy J. Immunol., March 15, 2009; 182(6): 3366 - 3371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jennings and D. Yuan NK Cell Enhancement of Antigen Presentation by B Lymphocytes J. Immunol., March 1, 2009; 182(5): 2879 - 2887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iguchi-Manaka, H. Kai, Y. Yamashita, K. Shibata, S. Tahara-Hanaoka, S.-i. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya Accelerated tumor growth in mice deficient in DNAM-1 receptor J. Exp. Med., December 22, 2008; 205(13): 2959 - 2964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. F. Werneck, G. Lugo-Villarino, E. S. Hwang, H. Cantor, and L. H. Glimcher T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease J. Immunol., June 15, 2008; 180(12): 8004 - 8010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth Clarification of data used in three studies on MCA-induction of sarcoma in mice Blood, April 15, 2008; 111(8): 4419 - 4419. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Berzofsky and M. Terabe NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis J. Immunol., March 15, 2008; 180(6): 3627 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Swann, M. D. Vesely, A. Silva, J. Sharkey, S. Akira, R. D. Schreiber, and M. J. Smyth Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis PNAS, January 15, 2008; 105(2): 652 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Greeneltch, M. Schneider, S. M. Steinberg, D. J. Liewehr, T. J. Stewart, K. Liu, and S. I. Abrams Host Immunosurveillance Controls Tumor Growth via IFN Regulatory Factor-8 Dependent Mechanisms Cancer Res., November 1, 2007; 67(21): 10406 - 10416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Swann, Y. Hayakawa, N. Zerafa, K. C. F. Sheehan, B. Scott, R. D. Schreiber, P. Hertzog, and M. J. Smyth Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function J. Immunol., June 15, 2007; 178(12): 7540 - 7549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E.A. Street, N. Zerafa, M. Iezzi, J. A. Westwood, J. Stagg, P. Musiani, and M. J. Smyth Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma Cancer Res., June 1, 2007; 67(11): 5454 - 5460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Coquet, K. Kyparissoudis, D. G. Pellicci, G. Besra, S. P. Berzins, M. J. Smyth, and D. I. Godfrey IL-21 Is Produced by NKT Cells and Modulates NKT Cell Activation and Cytokine Production J. Immunol., March 1, 2007; 178(5): 2827 - 2834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Gorbachev, H. Kobayashi, D. Kudo, C. S. Tannenbaum, J. H. Finke, S. Shu, J. M. Farber, and R. L. Fairchild CXC Chemokine Ligand 9/Monokine Induced by IFN-{gamma} Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors J. Immunol., February 15, 2007; 178(4): 2278 - 2286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Bui, R. Uppaluri, C.-S. Hsieh, and R. D. Schreiber Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins. Cancer Res., July 15, 2006; 66(14): 7301 - 7309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth, Y. Hayakawa, E. Cretney, N. Zerafa, P. Sivakumar, H. Yagita, and K. Takeda IL-21 Enhances Tumor-Specific CTL Induction by Anti-DR5 Antibody Therapy J. Immunol., May 15, 2006; 176(10): 6347 - 6355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth, M. W. L. Teng, J. Swann, K. Kyparissoudis, D. I. Godfrey, and Y. Hayakawa CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer J. Immunol., February 1, 2006; 176(3): 1582 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Bui, L. N. Carayannopoulos, L. L. Lanier, W. M. Yokoyama, and R. D. Schreiber IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors J. Immunol., January 15, 2006; 176(2): 905 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinha, V. K. Clements, and S. Ostrand-Rosenberg Interleukin-13-regulated M2 Macrophages in Combination with Myeloid Suppressor Cells Block Immune Surveillance against Metastasis Cancer Res., December 15, 2005; 65(24): 11743 - 11751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth, J. Swann, E. Cretney, N. Zerafa, W. M. Yokoyama, and Y. Hayakawa NKG2D function protects the host from tumor initiation J. Exp. Med., September 6, 2005; 202(5): 583 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Takaki, Y. Hayakawa, A. Nelson, P. V. Sivakumar, S. Hughes, M. J. Smyth, and L. L. Lanier IL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism J. Immunol., August 15, 2005; 175(4): 2167 - 2173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nishikawa, T. Kato, I. Tawara, T. Takemitsu, K. Saito, L. Wang, Y. Ikarashi, H. Wakasugi, T. Nakayama, M. Taniguchi, et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts PNAS, June 28, 2005; 102(26): 9253 - 9257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth, M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer J. Exp. Med., June 20, 2005; 201(12): 1973 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Duthie and S. J. Kahn NK cell activation and protection occur independently of natural killer T cells during Trypanosoma cruzi infection Int. Immunol., May 1, 2005; 17(5): 607 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Metelitsa, H.-W. Wu, H. Wang, Y. Yang, Z. Warsi, S. Asgharzadeh, S. Groshen, S. B. Wilson, and R. C. Seeger Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2 J. Exp. Med., May 3, 2004; 199(9): 1213 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E.A. Street, Y. Hayakawa, Y. Zhan, A. M. Lew, D. MacGregor, A. M. Jamieson, A. Diefenbach, H. Yagita, D. I. Godfrey, and M. J. Smyth Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and {gamma}{delta} T Cells J. Exp. Med., March 15, 2004; 199(6): 879 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Esteban, T. Tsoutsman, M. A. Jordan, D. Roach, L. D. Poulton, A. Brooks, O. V. Naidenko, S. Sidobre, D. I. Godfrey, and A. G. Baxter Genetic Control of NKT Cell Numbers Maps to Major Diabetes and Lupus Loci J. Immunol., September 15, 2003; 171(6): 2873 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hayakawa, S. Rovero, G. Forni, and M. J. Smyth {alpha}-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis PNAS, August 5, 2003; 100(16): 9464 - 9469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-L. Ma, M. J. Whitters, R. F. Konz, M. Senices, D. A. Young, M. J. Grusby, M. Collins, and K. Dunussi-Joannopoulos IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN-{gamma} J. Immunol., July 15, 2003; 171(2): 608 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Dhodapkar, M. D. Geller, D. H. Chang, K. Shimizu, S.-I. Fujii, K. M. Dhodapkar, and J. Krasovsky A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma J. Exp. Med., June 16, 2003; 197(12): 1667 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Stewart, M. J. Smyth, G. J. P. Fernando, I. H. Frazer, and G. R. Leggatt Inhibition of Early Tumor Growth Requires J{alpha}18-positive (Natural Killer T) Cells Cancer Res., June 15, 2003; 63(12): 3058 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Smyth and M. H. Kershaw Discovery of an Innate Cancer Resistance Gene? Mol. Interv., June 1, 2003; 3(4): 186 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. H. van Dommelen, H. A. Tabarias, M. J. Smyth, and M. A. Degli-Esposti Activation of Natural Killer (NK) T Cells during Murine Cytomegalovirus Infection Enhances the Antiviral Response Mediated by NK Cells J. Virol., February 1, 2003; 77(3): 1877 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Y. Crowe, M. J. Smyth, and D. I. Godfrey A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas J. Exp. Med., July 1, 2002; 196(1): 119 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Kelly, K. Takeda, P. K. Darcy, H. Yagita, and M. J. Smyth A Role for IFN-{gamma} in Primary and Secondary Immunity Generated by NK Cell-Sensitive Tumor-Expressing CD80 In Vivo J. Immunol., May 1, 2002; 168(9): 4472 - 4479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Trobonjaca, A. Kroger, D. Stober, F. Leithauser, P. Moller, H. Hauser, R. Schirmbeck, and J. Reimann Activating Immunity in the Liver. II. IFN-{beta} Attenuates NK Cell-Dependent Liver Injury Triggered by Liver NKT Cell Activation J. Immunol., April 15, 2002; 168(8): 3763 - 3770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth, N. Y. Crowe, D. G. Pellicci, K. Kyparissoudis, J. M. Kelly, K. Takeda, H. Yagita, and D. I. Godfrey Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha -galactosylceramide Blood, February 15, 2002; 99(4): 1259 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice J. Immunol., February 1, 2002; 168(3): 1356 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takeda, M. J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita, and K. Okumura Critical Role for Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development J. Exp. Med., January 14, 2002; 195(2): 161 - 169. [Abstract] [Full Text] [PDF]
|
|